Table 2.

League table of pairwise comparisons in network meta-analysis for COVID-19 vaccine efficacy from sensitivities analyses

After the first dose
P-score 1.000
mRNA	0.713
0.43 (0.28- 0.65)	Recombinant	0.513
0.34 (0.25- 0.45)	0.79 (0.55- 1.15)	DNA	0.274
0.29 (0.21- 0.39)	0.68 (0.45- 1.00)	0.85 (0.67- 1.08)	Inactivated	0.000
0.13 (0.10- 0.16)	0.30 (0.21- 0.42)	0.37 (0.33- 0.43)	0.44 (0.36- 0.53)	Control
Randomization to 21 days after dose 1
0.908
DNA	0.808
0.97 (0.65-1.43)	mRNA	0.457
0.70 (0.49-1.00)	0.72 (0.45-1.16)	Inactivated	0.167
0.57 (0.48-0.67)	0.59 (0.41-0.83)	0.81 (0.59-1.11)	Control	0.159
0.54 (0.34-0.87)	0.56 (0.32-0.99)	0.78 (0.45-1.34)	0.96 (0.62-1.49)	Recombinant
Starting 7 days after dose 2
0.963
mRNA	0.785
0.62 (0.25- 1.52)	Recombinant	0.460
0.23 (0.13- 0.40)	0.37 (0.16- 0.85)	Inactivated	0.293
0.21 (0.12- 0.36)	0.34 (0.15- 0.77)	0.92 (0.61- 1.41)	DNA	0.000
0.05 (0.03- 0.08)	0.08 (0.04- 0.18)	0.22 (0.16- 0.30)	0.24 (0.18- 0.32)	Control

Vaccines are ordered in the rank of their chance of being the best vaccine. Vaccine estimates are provided as incidence risk ratio (IRR) with 95% confidence interval. Comparisons between vaccines should be read left to right, and their IRR is in the cell in common between the column-defining vaccine and the row-defining vaccine. IRRs < 1 favor the column-defining vaccine for the network estimates. The values above the vaccines are the corresponding P-scores; Significant pairwise comparisons are highlighted (Bolded P values are < 0.05). mRNA: messenger RNA vaccines (BNT162b2 and mRNA-1273); DNA: adenoviral vaccines (Ad26.COV2.S, ChAdOx1 nCoV-19, and Gam-COVID-Vac); Inactivated vaccines (WIV04, HB02, and CoronaVac); and recombinant nanoparticle (NVX-CoV2373).